The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.
 
Tiffany A. Traina
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Genentech/Roche; Immunomedics; Medivation; Merck; Mundipharma; Pfizer
Research Funding - AstraZeneca; Eisai; Innocrin Pharma; Medivation; Myriad Genetics; Novartis; Pfizer
 
Denise A. Yardley
No Relationships to Disclose
 
Lee Steven Schwartzberg
Honoraria - Amgen; Bristol-Myers Squibb; Pfizer; Tesaro
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Helsinn Therapeutics; Pfizer
Speakers' Bureau - Genentech/Roche
Research Funding - Helsinn Therapeutics
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer
Travel, Accommodations, Expenses - Abbvie; Celgene; Lilly; Nektar; Novartis; Pfizer
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Celgene; Cellestia Biotech; Roche/Genentech
 
Ahmad Awada
No Relationships to Disclose
 
Catherine Margaret Kelly
No Relationships to Disclose
 
Maureen E. Trudeau
Stock and Other Ownership Interests - RNA Diagnostics
Honoraria - Pfizer
Consulting or Advisory Role - RNA Diagnostics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst)
Other Relationship - AstraZeneca; Eisai; Novartis; Roche Canada
 
Peter Schmid
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); Oncogenex (Inst)
 
Luca Gianni
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Boehringer Ingelheim; Celgene; Genomic Health; Lilly; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Synaffix; Synthon; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Roche
 
Ayca Gucalp
Research Funding - Innocrin Pharma; Pfizer
 
Laura Garcia-Estevez
No Relationships to Disclose
 
Rita Nanda
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Novartis; Peregrine Pharmaceuticals; Pfizer; Puma Biotechnology
Research Funding - Celgene; Corcept Therapeutics; Merck
 
Foluso Olabisi Ademuyiwa
No Relationships to Disclose
 
Stephen Chan
No Relationships to Disclose
 
Joyce Leta Steinberg
Employment - Astellas Pharma
Stock and Other Ownership Interests - Amgen (I)
Travel, Accommodations, Expenses - Astellas Pharma
 
Martha Elizabeth Blaney
Employment - Medivation
 
Iulia Cristina Tudor
Employment - Medivation
Stock and Other Ownership Interests - Medivation
Travel, Accommodations, Expenses - Medivation
 
Hirdesh Uppal
Employment - Medivation
 
Kathy Miller
Consulting or Advisory Role - Nektar; Tesaro
Research Funding - Clovis Oncology (Inst); EntreMed (Inst); Genentech (Inst); Macrogenics (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)